A commonly prescribed antidiabetic drug may have an unexpected role in reducing one of the most frequent long-term complications of cataract surgery, according to new laboratory and translational data published in the British Journal of Ophthalmology.
Posterior capsule opacification (PCO) develops in approximately 20%–30% of patients within five years of cataract surgery and remains the most frequent long-term issue after otherwise successful phacoemulsification. Although Nd:YAG laser capsulotomy is effective as a rapid treatment for PCO, it still carries some risks, including elevated intraocular pressure, cystoid macular edema, and retinal detachment.
Residual lens epithelial cells (LECs) that proliferate, migrate, and undergo epithelial–mesenchymal transition are central to PCO pathogenesis. Responding to recent studies and clinical data indicating that metformin can suppress LEC proliferation and senescence, as well as reduce Nd: YAG rates, investigators from Vienna examined whether systemically administered metformin reaches the human lens capsule and whether concentrations achieved in vivo are sufficient to influence LEC proliferation.
In the prospective single-center study, which included 20 patients with type 2 diabetes mellitus undergoing cataract surgery and treated with oral metformin, the researchers used high-performance liquid chromatography–tandem mass spectrometry to quantify metformin levels in both serum and excised anterior lens capsules. Metformin was detectable in all capsule specimens. Importantly, capsule and serum concentrations were significantly correlated, supporting the concept that systemic exposure translates into measurable intraocular tissue levels.
Capsule concentrations did not differ significantly between low-dose and high-dose groups, suggesting that lens capsule exposure may not scale linearly with prescribed dose. Serum levels showed variability, consistent with known interindividual differences in metformin pharmacokinetics.
To assess functional relevance, the team conducted in vitro proliferation assays using anterior lens capsules from non-diabetic donors. Explants were cultured for 14 days with or without metformin at 0.75 pg/µL, a concentration corresponding to mean intracapsular levels measured in patients in the previous experiments.
Live-cell imaging at eight-hour intervals demonstrated a significant time-by-treatment interaction, indicating that metformin attenuated LEC proliferation compared with controls. Although growth was not completely arrested, treated samples showed reduced expansion and fewer spindle-like outgrowths resembling those seen clinically in PCO.
Clinically, the results offer a potential explanation for previously conflicting data regarding diabetes and PCO risk. Some epidemiologic studies have suggested a protective effect, while others have reported increased risk with longer disease duration. The authors propose that "these discrepancies may result from a failure to stratify patients by antidiabetic medication," and that metformin use – rather than diabetes itself – may be an important modifying factor of PCO risk.
While intraocular lens design remains the cornerstone of PCO prevention, the data raise the possibility that systemic or locally delivered pharmacologic strategies could act as a pharmacological adjunct for current mechanical barrier approaches. The authors emphasize that larger studies are now needed, but conclude that their findings provide the first direct evidence that systemically administered metformin accumulates in the human lens capsule and suppresses LEC proliferation at physiologically relevant concentrations.
Source: British Journal of Ophthalmology.
Posterior capsule opacification (PCO) develops in approximately 20%–30% of patients within five years of cataract surgery and remains the most frequent long-term issue after otherwise successful phacoemulsification. Although Nd:YAG laser capsulotomy is effective as a rapid treatment for PCO, it still carries some risks, including elevated intraocular pressure, cystoid macular edema, and retinal detachment.
Residual lens epithelial cells (LECs) that proliferate, migrate, and undergo epithelial–mesenchymal transition are central to PCO pathogenesis. Responding to recent studies and clinical data indicating that metformin can suppress LEC proliferation and senescence, as well as reduce Nd: YAG rates, investigators from Vienna examined whether systemically administered metformin reaches the human lens capsule and whether concentrations achieved in vivo are sufficient to influence LEC proliferation.
In the prospective single-center study, which included 20 patients with type 2 diabetes mellitus undergoing cataract surgery and treated with oral metformin, the researchers used high-performance liquid chromatography–tandem mass spectrometry to quantify metformin levels in both serum and excised anterior lens capsules. Metformin was detectable in all capsule specimens. Importantly, capsule and serum concentrations were significantly correlated, supporting the concept that systemic exposure translates into measurable intraocular tissue levels.
Capsule concentrations did not differ significantly between low-dose and high-dose groups, suggesting that lens capsule exposure may not scale linearly with prescribed dose. Serum levels showed variability, consistent with known interindividual differences in metformin pharmacokinetics.
To assess functional relevance, the team conducted in vitro proliferation assays using anterior lens capsules from non-diabetic donors. Explants were cultured for 14 days with or without metformin at 0.75 pg/µL, a concentration corresponding to mean intracapsular levels measured in patients in the previous experiments.
Live-cell imaging at eight-hour intervals demonstrated a significant time-by-treatment interaction, indicating that metformin attenuated LEC proliferation compared with controls. Although growth was not completely arrested, treated samples showed reduced expansion and fewer spindle-like outgrowths resembling those seen clinically in PCO.
Clinically, the results offer a potential explanation for previously conflicting data regarding diabetes and PCO risk. Some epidemiologic studies have suggested a protective effect, while others have reported increased risk with longer disease duration. The authors propose that "these discrepancies may result from a failure to stratify patients by antidiabetic medication," and that metformin use – rather than diabetes itself – may be an important modifying factor of PCO risk.
While intraocular lens design remains the cornerstone of PCO prevention, the data raise the possibility that systemic or locally delivered pharmacologic strategies could act as a pharmacological adjunct for current mechanical barrier approaches. The authors emphasize that larger studies are now needed, but conclude that their findings provide the first direct evidence that systemically administered metformin accumulates in the human lens capsule and suppresses LEC proliferation at physiologically relevant concentrations.
Source: British Journal of Ophthalmology.
